UPLOAD Filing
TENAX THERAPEUTICS, INC.
Date: March 27, 2026 · CIK: 0000034956 · Accession: 0000000000-26-003148
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-294561
Letter
Re: Tenax Therapeutics, Inc. Registration Statement on Form S-3 Filed March 24, 2026 File No. 333-294561 Dear Christopher Giordano:
March 27, 2026
Christopher Giordano Chief Executive Officer Tenax Therapeutics, Inc. 101 Glen Lennox Drive, Suite 300 Chapel Hill, NC 27517
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Lauren Hamill at 303-844-1008 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Lorna Knick
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> March 27, 2026 Christopher Giordano Chief Executive Officer Tenax Therapeutics, Inc. 101 Glen Lennox Drive, Suite 300 Chapel Hill, NC 27517 Re: Tenax Therapeutics, Inc. Registration Statement on Form S-3 Filed March 24, 2026 File No. 333-294561 Dear Christopher Giordano: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Lauren Hamill at 303-844-1008 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Lorna Knick </TEXT> </DOCUMENT>